User login
Determinants of Suboptimal Migraine Diagnosis and Treatment in the Primary Care Setting
From the Mayo Clinic, Scottsdale, AZ.
Abstract
- Objective: To review the impact of migraine and explore the barriers to optimal migraine diagnosis and treatment.
- Methods: Review of the literature.
- Results: Several factors may play a role in the inadequate care of migraine patients, including issues related to poor access to care, diagnostic insight, misdiagnosis, adherence to treatment, and management of comorbidities. Both patient and physician factors play an important role and many be modifiable.
- Conclusions: A focus on education of both patients and physicians is of paramount importance to improve the care provided to migraine patients. Patient evaluations should be multisystemic and include addressing comorbid conditions as well as a discussion about appropriate use of prevention and avoidance of medication overuse.
Key words: migraine; triptans; medication overuse headache; medication adherence; primary care.
Migraine is a common, debilitating condition that is a significant source of reduced productivity and increased disability [1]. According to the latest government statistics, 14.2% of US adults have reported having migraine or severe headaches in the previous 3 months, with an overall age-adjusted 3-month prevalence of 19.1% in females and 9.0% in males [2]. In a self-administered headache questionnaire mailed to 120,000 representative US households, the 1-year period prevalence for migraine was 11.7% (17.1% in women and 5.6% in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years [3]. Migraine is an important cause of reduced health-related quality of life and has a very high economic burden [4]. This effect is even more marked in those with chronic migraine, who are even more likely to have professional and social absenteeism and experience more severe disability [4].
Migraine and headache are a common reason for primary care physician (PCP) visits. Some estimates suggest that as many as 10% of primary care consultations are due to headache [5]. Approximately 75% of all patients complaining of headache in primary care will eventually be diagnosed with migraine [6]. Of these, as many as 1% to 5% will have chronic migraine [6].
Despite the high frequency and social and economic impact of migraine, migraine is underrecognized and undertreated. A survey of US households revealed that only 13% of migraineurs were currently using a preventive thrapy while 43.3% had never used one [3]. This is despite the fact that 32.4% met expert criteria for consideration of a preventive medication [3]. The reasons for underrecognition and undertreatment are multifactorial and include both patient and physician factors.
Physician Factors
Although migraine and headache are a leading cause of physicians visits, most physicians have had little formal training in headache. In the United States, medical students spend an average of 1 hour of preclinical and 2 hours of clinical education in headache [7]. Furthermore, primary care physicians receive little formal training in headache during residency [8]. In addition to the lack of formal training, there is also a lack of substantial clinic time available to fully evaluate and treat a new headache patient in the primary care setting [8]. Headache consultations can often be timely and detail-driven in order to determine the correct diagnosis and treatment [9].
Misdiagnosis
Evidence suggests that misdiagnosis plays a large role in the suboptimal management of migraineurs. Studies have shown that as many as 59.7% of migraineurs were not given a diagnosis of migraine by their primary care provider [10]. Common mistaken diagnoses include tension-type headache [11], “sinus headache” [12], cervical pain syndrome or cervicogenic headache [13], and “stress headache” [14].
The reasons for these misdiagnoses is not certain. It may be that the patient and practitioner assume that location of the pain is suggestive of the cause [13]. This is even though more than half of those with migraine have associated neck pain [15]. A recent study suggests that 60% of migraineurs who self-reported a diagnosis of cervical pain have been subsequently diagnosed with cervicalgia by a physician [13]. If patients endorse stress as a precipitant or the presence of cervical pain, they are more likely to obtain a diagnosis other than migraine. The presence of aura in association with the headache appears to be protective against misdiagnosis [13].
Similarly, patients are often given a diagnosis of “sinus headache.” This diagnosis is often made without radiologic evidence of sinusitis and even in those with a more typical migraine headache [16]. In one survey, 40% of patients meeting criteria for migraine were given this diagnosis. Many of these patients did have nasal symptoms or facial pain without clear evidence or rhinosinusitis, and in some cases these symptoms would respond to migraine treatments [16]. This is a particularly important misdiagnosis to highlight, as attributing symptoms to sinus disease may lead to unnecessary consultations and even sinus instrumentation.
In addition to common misdiagnoses, many PCPs are unfamiliar with the “red flags” that may indicate a secondary headache disorder and are also unfamiliar with appropriate use of neuroimaging in headache patients [17].
Misuse of As-Needed Medications
Studies have suggested that a large proportion of PCPs will prescribe nonspecific analgesics for migraine rather than migraine-specific medications [18]. These treatments may include NSAIDs, acetaminophen, barbiturates, and even opiates. This appears to be the pattern even for those with severe attacks [18], suggesting that migraine-specific medications such as triptans may be underused in the primary care setting. Postulated reasons for this pattern include lack of physician knowledge regarding the specific recommendations for managing migraine, the cost of medications, as well as lack of insurance coverage for these medications [19]. Misuse of as-needed medications can lead to medication overuse headache (MOH), which is an underrecognized problem in the primary care setting [20]. In a survey of PCPs in Boston, only 54% of PCPs were aware that barbiturates can cause MOH and only 34% were aware that opiates can cause MOH [17]. The same survey revealed that approximately 20% of PCPs had never made the diagnosis of MOH [17].
Underuse of Preventive Medications
As many as 40% of migraineurs need preventive therapy, but only approximately 13% are currently receiving it [3]. Additionally, the average time from diagnosis of migraine to instituting preventive treatment is 4.3 years, and often there is only a single preventive medication trial if one is instituted [21]. The reasons for this appear to be complex. The physician factors contributing to the underuse of preventive medications include inadequate education, discomfort and inadequate time for assessments. Only 27.8% of surveyed PCPs were aware of the American Academy of Neurology guidelines for prescribing preventive medications [17].
There may be an underestimate of the disability experienced by migraineurs, which can explain some of the underuse of preventive medications. While many PCPs endorse inquiring about headache-related disability, many do not used validated scales such as the Migraine Disability Assessment Score (MIDAS) or the Headache Impact Test (HIT) [17]. In addition, patients often underreport their headache days and report only their severe exacerbations unless clearly asked about a daily headache [22]. This may be part of the reason why only 20% of migraineurs who meet criteria for chronic migraine are diagnosed as such and why preventatives may not be offered [23].
After preventatives are started, less than 25% of patients will be adherent to oral migraine preventive agents at 1 year [24]. Common reasons for discontinuing preventives include adverse effects and perceived inefficacy [22]. Preventive medications may need a 6- to 8-week trial before efficacy is determined, but in practice medications may be stopped before this threshold is reached. Inadequate follow-up and lack of detail with regard to medication trials may result in the perception of an intractable patient prematurely. It has been suggested that a systematic approach to documenting and choosing preventive agents is helpful in the treatment of migraine [25], although this is not always practical in the primary care setting.
Another contributor to underuse of effective prophylaxis is related to access. Treatment with onabotulinumtoxin A, an efficacious prophylactic treatment approved for select chronic migraine patients [26], will usually require referral to a headache specialist, which is not always available to PCPs in a timely manner [7].
Nonpharmacologic Approaches
Effective nonpharmacologic treatment modalities for migraine, such as cognitive-behavioral therapy and biofeedback [27], are not commonly recommended by PCPs [17]. Instead, there appears to be more focus on avoidance of triggers and referral to non–evidence-based resources, such as special diets and massage therapy [17]. While these methods are not always inappropriate, it should be noted that they often have little or no evidence for efficacy.
Patients often wish for non-medication approaches to migraine management, but for those with significant and severe disability, these are probably insufficient. In these patients, non-medication approaches may best be used as a supplement to pharmacological treatment, with education on pharmacologic prevention given. Neuromodulation is a promising, novel approach that is emerging as a new treatment for migraine, but likely will require referral to a headache specialist.
Suboptimal Management of Migraine Comorbidities
There are several disorders that are commonly comorbid with migraine. Among the most common are anxiety, depression, medication (and caffeine) overuse, obesity, and sleep disorders [22]. A survey of PCPs reveals that only 50.6% of PCPs screen for anxiety, 60.2% for depression, and 73.5% for sleep disorders [17]. They are, for the most part, modifiable or treatable conditions and their proper management may help ease migraine disability.
In addition, the presence of these comorbidities may alter choice of treatment, for example, favoring the use of an serotonin and norepinephrine reuptake inhibitor such as venlafaxine for treatment in those with comorbid anxiety and depression. It is also worthwhile to have a high index of suspicion for obstructive sleep apnea in patients with headache, particularly in the obese and in those who endorse nonrestorative sleep or excessive daytime somnolence. It appears that patients who are adherent to the treatment of sleep apnea are more likely to report improvement in their headache [28].
Given the time constraints that often exist in the PCP office setting, addressing these comorbidities thoroughly is not always possible. It is reasonable, however, to have patients use screening tools while in the waiting room or prior to an appointment, to better identify those with modifiable comorbidities. Depression, anxiety, and excessive daytime sleepiness can all be screened for relatively easily with tools such as the PHQ-9 [29], GAD-7 [30] and Epworth Sleepiness Scale [31], respectively. A positive screen on any of these could lead the PCP to further investigate these entities as a possible contributor to migraine.
Patient Factors
In addition to the physician factors identified above, patient factors can contribute to the suboptimal management of migraine as well. These factors include a lack insight into diagnosis, poor compliance with treatment of migraine or its comorbidities, and overuse of abortive medications. There are also less modifiable patient factors such as socioeconomic status and the stigma that may be associated with migraine.
Poor Insight Into Diagnosis
Despite the high prevalence and burden of migraine in the general population, there is a staggering lack of awareness among migraineurs. Some estimates state that as many as 54% of patients were unaware that their headaches represented migraine [32]. The most common self-reported diagnoses in migraineurs are sinus headache (39%), tension-type headache (31%) and stress headache (29%) [14]. In addition, many patients believe they are suffering from cervical spine–related pain [13]. This is likely due to the common presence of posteriorly located pain, attacks triggered by poor sleep, or attacks associated with weather changes [13]. Patients presenting with aura are more likely to report and to receive a physician diagnosis of migraine [14]. Women are more likely to receive and report a diagnosis of migraine compared with men [32].
There are many factors that play a role in poor insight. Many patients appear to believe that the location of the pain is suggestive of the cause [13]. Many patients never seek out consultation for their headaches, and thus never receive a proper diagnosis [33]. Some patients may seek out medical care for their headaches, but fail to remember their diagnosis or receive an improper diagnosis [34].
Poor Adherence
The body of literature examining adherence with headache treatment is growing, but remains small [35]. In a recent systematic review of treatment adherence in pediatric and adult patients with headache, adherence rates in adults with headache ranged from 25% to 94% [35]. In this review, prescription claims data analyses found poor persistence in patients prescribed triptans for migraine treatment. In one large claims-based study, 53.8% of patients receiving a new triptan prescription did not persistently refill their index triptan [36]. Although some of these patients switched to an alternative triptan, the majority switched to a non-triptan migraine medication, including opioids and nonsteroidal anti-inflammatory drugs [36].
Cady and colleagues’ study of lapsed and sustained triptan users found that sustained users were significantly more satisfied with their medication, confident in the medication’s ability to control headache, and reported control of migraine with fewer doses of medication [37]. The authors concluded that the findings suggest that lapsed users may not be receiving optimal treatment. In a review by Rains et al [38], the authors found that headache treatment adherence declines “with more frequent and complex dosing regimens, side effects, and costs, and is subject to a wide range of psychosocial influences.”
Adherence issues also exist for migraine prevention. Less than 25% of chronic migraine patients continue to take oral preventive therapies at 1 year [24]. The reasons for this nonadherence are not completely clear, but are likely multifactorial. Preventives may take several weeks to months to become effective, which may contribute to noncompliance. In addition, migraineurs appears to have inadequate follow-up for migraine. Studies from France suggest that only 18% of those aware of their migraine diagnosis received medical follow-up [39].
Medication Overuse
While the data is not entirely clear, it is likely that overuse of as-needed medication plays a role in migraine chronification [40]. The reasons for medication overuse in the migraine population include some of the issues already highlighted above, including inadequate patient education, poor insight into diagnosis, not seeking care, misdiagnosis, and treatment nonadherence. Patients should be educated on the proper use of as-needed medication. Limits to medication use should be set during the physician-patient encounter. Patients should be counselled to limit their as-needed medication to no more than 10 days per month to reduce the risk of medication overuse headache. Ideally, opiates and barbiturates should be avoided, and never used as first-line therapy in patients who lack contraindications to NSAIDs and triptans. If their use in unavoidable for other reasons, they should be used sparingly, as use on as few as 5 to 8 days per month can be problematic [41]. Furthermore it is important to note that if patients are using several different acute analgesics, the combined total use of all as-needed pain medications needs to be less than 10 days per month to reduce the potential for medication overuse headache.
Socioeconomic Factors
Low socioeconomic status has been associated with an increased prevalence for all headache forms and an increased migraine attack frequency [42], but there appear to be few studies looking at the impact of low socioeconomic status and treatment. Lipton et al found that health insurance status was an important predictor of persons with migraine consulting a health care professional [43]. Among consulters, women were far more likely to be diagnosed than men, suggesting that gender bias in diagnosis may be an important barrier for men. Higher household income appeared to be a predictor for receiving a correct diagnosis of migraine. These researchers also found economic barriers related to use of appropriate prescription medications [43]. Differences in diagnosis and treatment may indicate racial and ethnic disparities in access and quality of care for minority patients [44].
Stigma
At least 1 study has reported that migraine patients experience stigma. In Young et al’s study of 123 episodic migraine patients, 123 chronic migraine patients, and 62 epilepsy patients, adjusted stigma was similar for chronic migraine and epilepsy, which were greater than for episodic migraine [45]. Stigma correlated most strongly with inability to work. Migraine patients reported equally high stigma scores across age, income, and education. The stigma of migraine may pose a barrier to seeking consultation and treatment. Further, the perception that migraine is “just a headache” may lead to stigmatizing attitudes on the part of friends, family, and coworkers of patients with migraine.
Conclusions and Recommendations
Migraine is a prevalent and frequently disabling condition that is underrecognized and undertreated in the primary care setting. Both physician and patient factors pose barriers to the optimal diagnosis and treatment of migraine. Remedies to address these barriers include education of both patients and physicians first and foremost. Targeting physician education in medical school and during residency training, including in primary care subspecialties, could include additional didactic teaching, but also clinical encounters in headache subspecialty clinics to increase exposure. Patient advocacy groups and public campaigns to improve understanding of migraine in the community may be a means for improving patient education and reducing stigma. Patients should be encouraged to seek out consultations for headache to reduce long-term headache disability. Management of comorbidities is paramount, and screening tools for migraine-associated disability, anxiety, depression, and medication use may be helpful to implement in the primary care setting as they are easy to use and time saving.
Recent surveys of PCPs suggest that the resource that is most desired is ready access to subspecialists for advice and “curb-side” consultation [17]. While this solution is not always practical, it may be worthwhile exploring closer relationships between primary care and subspecialty headache clinics, or perhaps more access to e-consultation or telephone consultation for more rural areas. Recently, Minen et al examined education strategies for PCPs. While in-person education sessions with PCPs were poorly attended, multiple possibilities for further education were identified. It was suggested that PCPs having real-time access to resources during the patient encounter would improve their comfort in managing patients. This includes online databases, simple algorithms for treatment, and directions for when to refer to a neurologist [46]. In addition, it may be worthwhile to train not only PCPs but also nursing and allied health staff so that they can provide headache education to patients. This may help ease some of the time burden on PCPs as well as provide a collaborative environment in which headache can be managed [46].
Corresponding author: William S. Kingston, MD, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259.
Financial disclosures: None.
1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity and attack frequency and duration. Neurology 1994; 44(suppl 4):S24–S39
2. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015;55:21–34.
3. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–9.
4. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use amoung chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301–15.
5. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain 2012;6:124–32.
6. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systemic review. Cephalalgia 2010;30: 599–609.
7. Finkel AG. American academic headache specialists in neurology: Practice characteristics and culture. Cephalalgia 2004; 24:522–7.
8. Sheftell FD, Cady RK, Borchert LD, et al. Optimizing the diagnosis and treatment of migraine. J Am Acad Nurse Pract 2005;17:309–17.
9. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003;60:441–8.
10. De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: Influence of functional impact measures by the Headache Impact Test (HIT). Cephalalgia 2005;25:184–90.
11. Miller S, Matharu MS. Migraine is underdiagnosed and undertreated. Practitioner 2014;258:19–24.
12. Al-Hashel JY, Ahmed SF, Alroughani R, et al. Migraine misdiagnosis as sinusitis, a delay that can last for many years. J Headache Pain 2013;14:97.
13. Viana M, Sances G, Terrazzino S, et al. When cervical pain is actually migraine: an observational study in 207 patients. Cephalalgia 2016. Epub ahead of print.
14. Diamond MD, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache 2007;47:355–63.
15. Aguila MR, Rebbeck T, Mendoza KG, et al. Definitions and participant characteristics of frequent recurrent headache types in clinical trials: A systematic review. Cephalalgia 2017. Epub ahead of print.
16. Senbil N, Yavus Gurer YK, Uner C, Barut Y. Sinusitis in children and adolescents with chronic or recurrent headache: A case-control study. J Headache Pain 2008;9:33–6.
17. Minen MT, Loder E, Tishler L, Silbersweig D. Migraine diagnosis and treatment: A knowledge and needs assessment amoung primary care providers. Cephalalgia 2016; 36:358–70.
18. MacGregor EA, Brandes J, Eikerman A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache 2003;33:19–26.
19. Khan S, Mascarenhas A, Moore JE, et al. Access to triptans for acute episodic migraine: a qualitative study. Headache 2015; 44(suppl 4):199–211.
20. Tepper SJ. Medication-overuse headache. Continuum 2012;18:807–22.
21. Dekker F, Dielemann J, Neven AK, et al. Preventive treatment for migraine in primary care, a population based study in the Netherlands. Cephalalgia 2013;33:1170–8.
22. Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis and management in primary care. Mayo Clin Proc 2015;90:408–14.
23. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559–66.
24. Hepp Z, Dodick D, Varon S, et al. Adherence to oral migraine preventive-medications among patients with chronic migraine. Cephalalgia 2015;35:478–88.
25. Smith JH, Schwedt TJ. What constitutes an “adequate” trial in migraine prevention? Curr Pain Headache Rep 2015;19:52.
26. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–36.
27. Silberstein SD. Practice parameter: evidence based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754–62.
28. Johnson KG, Ziemba AM, Garb JL. Improvement in headaches with continuous positive airway pressure for obstructive sleep apnea: a retrospective analysis. Headache 2013;53:333–43.
29. Altura KC, Patten SB, FIest KM, et al. Suicidal ideation in persons with neurological conditions: prevalence, associations and validation of the PHQ-9 for suicidal ideation. Gen Hosp Psychiatry 2016;42:22–6.
30. Seo JG, Park SP. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 2015;16:97.
31. Corlateanu A, Pylchenko S, DIrcu V, Botnaru V. Predictors of daytime sleepiness in patients with obstructive sleep apnea. Pneumologia 2015;64:21–5.
32. Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs – a nation-wide population-based survey in Sweden. Cephalalgia 2004;24:455–65.
33. Osterhaus JT, Gutterman DL, Plachetka JR. Health care resources and lost labor costs of migraine headaches in the United States. Pharmacoeconomics 1992;36:69–76.
34. Tepper SJ, Dahlof CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache 2004;44:856–64.
35. Ramsey RR, Ryan JL, Hershey AD, et al. Treatment adherence in patients with headache: a systematic review. Headache 2014;54:795–816.
36. Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia 2011;31:488–500.
37. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK. Predictors of adherence to triptans: factors of sustained vs lapsed users. Headache 2009;49:386–94.
38. Rains JC, Lipchik GL, Penzien DB. Behavioral facilitation of medical treatment for headache--part I: Review of headache treatment compliance. Headache 2006;46:1387–94.
39. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005;25:267–79.
40. Bigal ME, Serrano D, Buse D et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157–68.
41. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004;3:475–83.
42. Winter AC, Berger K, Buring JE, Kurth T. Associations of socioeconomic status with migraine and non-migraine headache. Cephalalgia 2012;32:159–70.
43. Lipton, RB, Serrano D, Holland S et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013;53: 81–92.
44. Loder S, Sheikh HU, Loder E. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. Headache 2015;55:214–28.
45. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013;8:e54074.
46. Minen A, Shome A, Hapern A, et al. A migraine training program for primary care providers: an overview of a survey and pilot study findings, lessons learned, and consideration for further research. Headache 2016;56:725–40.
From the Mayo Clinic, Scottsdale, AZ.
Abstract
- Objective: To review the impact of migraine and explore the barriers to optimal migraine diagnosis and treatment.
- Methods: Review of the literature.
- Results: Several factors may play a role in the inadequate care of migraine patients, including issues related to poor access to care, diagnostic insight, misdiagnosis, adherence to treatment, and management of comorbidities. Both patient and physician factors play an important role and many be modifiable.
- Conclusions: A focus on education of both patients and physicians is of paramount importance to improve the care provided to migraine patients. Patient evaluations should be multisystemic and include addressing comorbid conditions as well as a discussion about appropriate use of prevention and avoidance of medication overuse.
Key words: migraine; triptans; medication overuse headache; medication adherence; primary care.
Migraine is a common, debilitating condition that is a significant source of reduced productivity and increased disability [1]. According to the latest government statistics, 14.2% of US adults have reported having migraine or severe headaches in the previous 3 months, with an overall age-adjusted 3-month prevalence of 19.1% in females and 9.0% in males [2]. In a self-administered headache questionnaire mailed to 120,000 representative US households, the 1-year period prevalence for migraine was 11.7% (17.1% in women and 5.6% in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years [3]. Migraine is an important cause of reduced health-related quality of life and has a very high economic burden [4]. This effect is even more marked in those with chronic migraine, who are even more likely to have professional and social absenteeism and experience more severe disability [4].
Migraine and headache are a common reason for primary care physician (PCP) visits. Some estimates suggest that as many as 10% of primary care consultations are due to headache [5]. Approximately 75% of all patients complaining of headache in primary care will eventually be diagnosed with migraine [6]. Of these, as many as 1% to 5% will have chronic migraine [6].
Despite the high frequency and social and economic impact of migraine, migraine is underrecognized and undertreated. A survey of US households revealed that only 13% of migraineurs were currently using a preventive thrapy while 43.3% had never used one [3]. This is despite the fact that 32.4% met expert criteria for consideration of a preventive medication [3]. The reasons for underrecognition and undertreatment are multifactorial and include both patient and physician factors.
Physician Factors
Although migraine and headache are a leading cause of physicians visits, most physicians have had little formal training in headache. In the United States, medical students spend an average of 1 hour of preclinical and 2 hours of clinical education in headache [7]. Furthermore, primary care physicians receive little formal training in headache during residency [8]. In addition to the lack of formal training, there is also a lack of substantial clinic time available to fully evaluate and treat a new headache patient in the primary care setting [8]. Headache consultations can often be timely and detail-driven in order to determine the correct diagnosis and treatment [9].
Misdiagnosis
Evidence suggests that misdiagnosis plays a large role in the suboptimal management of migraineurs. Studies have shown that as many as 59.7% of migraineurs were not given a diagnosis of migraine by their primary care provider [10]. Common mistaken diagnoses include tension-type headache [11], “sinus headache” [12], cervical pain syndrome or cervicogenic headache [13], and “stress headache” [14].
The reasons for these misdiagnoses is not certain. It may be that the patient and practitioner assume that location of the pain is suggestive of the cause [13]. This is even though more than half of those with migraine have associated neck pain [15]. A recent study suggests that 60% of migraineurs who self-reported a diagnosis of cervical pain have been subsequently diagnosed with cervicalgia by a physician [13]. If patients endorse stress as a precipitant or the presence of cervical pain, they are more likely to obtain a diagnosis other than migraine. The presence of aura in association with the headache appears to be protective against misdiagnosis [13].
Similarly, patients are often given a diagnosis of “sinus headache.” This diagnosis is often made without radiologic evidence of sinusitis and even in those with a more typical migraine headache [16]. In one survey, 40% of patients meeting criteria for migraine were given this diagnosis. Many of these patients did have nasal symptoms or facial pain without clear evidence or rhinosinusitis, and in some cases these symptoms would respond to migraine treatments [16]. This is a particularly important misdiagnosis to highlight, as attributing symptoms to sinus disease may lead to unnecessary consultations and even sinus instrumentation.
In addition to common misdiagnoses, many PCPs are unfamiliar with the “red flags” that may indicate a secondary headache disorder and are also unfamiliar with appropriate use of neuroimaging in headache patients [17].
Misuse of As-Needed Medications
Studies have suggested that a large proportion of PCPs will prescribe nonspecific analgesics for migraine rather than migraine-specific medications [18]. These treatments may include NSAIDs, acetaminophen, barbiturates, and even opiates. This appears to be the pattern even for those with severe attacks [18], suggesting that migraine-specific medications such as triptans may be underused in the primary care setting. Postulated reasons for this pattern include lack of physician knowledge regarding the specific recommendations for managing migraine, the cost of medications, as well as lack of insurance coverage for these medications [19]. Misuse of as-needed medications can lead to medication overuse headache (MOH), which is an underrecognized problem in the primary care setting [20]. In a survey of PCPs in Boston, only 54% of PCPs were aware that barbiturates can cause MOH and only 34% were aware that opiates can cause MOH [17]. The same survey revealed that approximately 20% of PCPs had never made the diagnosis of MOH [17].
Underuse of Preventive Medications
As many as 40% of migraineurs need preventive therapy, but only approximately 13% are currently receiving it [3]. Additionally, the average time from diagnosis of migraine to instituting preventive treatment is 4.3 years, and often there is only a single preventive medication trial if one is instituted [21]. The reasons for this appear to be complex. The physician factors contributing to the underuse of preventive medications include inadequate education, discomfort and inadequate time for assessments. Only 27.8% of surveyed PCPs were aware of the American Academy of Neurology guidelines for prescribing preventive medications [17].
There may be an underestimate of the disability experienced by migraineurs, which can explain some of the underuse of preventive medications. While many PCPs endorse inquiring about headache-related disability, many do not used validated scales such as the Migraine Disability Assessment Score (MIDAS) or the Headache Impact Test (HIT) [17]. In addition, patients often underreport their headache days and report only their severe exacerbations unless clearly asked about a daily headache [22]. This may be part of the reason why only 20% of migraineurs who meet criteria for chronic migraine are diagnosed as such and why preventatives may not be offered [23].
After preventatives are started, less than 25% of patients will be adherent to oral migraine preventive agents at 1 year [24]. Common reasons for discontinuing preventives include adverse effects and perceived inefficacy [22]. Preventive medications may need a 6- to 8-week trial before efficacy is determined, but in practice medications may be stopped before this threshold is reached. Inadequate follow-up and lack of detail with regard to medication trials may result in the perception of an intractable patient prematurely. It has been suggested that a systematic approach to documenting and choosing preventive agents is helpful in the treatment of migraine [25], although this is not always practical in the primary care setting.
Another contributor to underuse of effective prophylaxis is related to access. Treatment with onabotulinumtoxin A, an efficacious prophylactic treatment approved for select chronic migraine patients [26], will usually require referral to a headache specialist, which is not always available to PCPs in a timely manner [7].
Nonpharmacologic Approaches
Effective nonpharmacologic treatment modalities for migraine, such as cognitive-behavioral therapy and biofeedback [27], are not commonly recommended by PCPs [17]. Instead, there appears to be more focus on avoidance of triggers and referral to non–evidence-based resources, such as special diets and massage therapy [17]. While these methods are not always inappropriate, it should be noted that they often have little or no evidence for efficacy.
Patients often wish for non-medication approaches to migraine management, but for those with significant and severe disability, these are probably insufficient. In these patients, non-medication approaches may best be used as a supplement to pharmacological treatment, with education on pharmacologic prevention given. Neuromodulation is a promising, novel approach that is emerging as a new treatment for migraine, but likely will require referral to a headache specialist.
Suboptimal Management of Migraine Comorbidities
There are several disorders that are commonly comorbid with migraine. Among the most common are anxiety, depression, medication (and caffeine) overuse, obesity, and sleep disorders [22]. A survey of PCPs reveals that only 50.6% of PCPs screen for anxiety, 60.2% for depression, and 73.5% for sleep disorders [17]. They are, for the most part, modifiable or treatable conditions and their proper management may help ease migraine disability.
In addition, the presence of these comorbidities may alter choice of treatment, for example, favoring the use of an serotonin and norepinephrine reuptake inhibitor such as venlafaxine for treatment in those with comorbid anxiety and depression. It is also worthwhile to have a high index of suspicion for obstructive sleep apnea in patients with headache, particularly in the obese and in those who endorse nonrestorative sleep or excessive daytime somnolence. It appears that patients who are adherent to the treatment of sleep apnea are more likely to report improvement in their headache [28].
Given the time constraints that often exist in the PCP office setting, addressing these comorbidities thoroughly is not always possible. It is reasonable, however, to have patients use screening tools while in the waiting room or prior to an appointment, to better identify those with modifiable comorbidities. Depression, anxiety, and excessive daytime sleepiness can all be screened for relatively easily with tools such as the PHQ-9 [29], GAD-7 [30] and Epworth Sleepiness Scale [31], respectively. A positive screen on any of these could lead the PCP to further investigate these entities as a possible contributor to migraine.
Patient Factors
In addition to the physician factors identified above, patient factors can contribute to the suboptimal management of migraine as well. These factors include a lack insight into diagnosis, poor compliance with treatment of migraine or its comorbidities, and overuse of abortive medications. There are also less modifiable patient factors such as socioeconomic status and the stigma that may be associated with migraine.
Poor Insight Into Diagnosis
Despite the high prevalence and burden of migraine in the general population, there is a staggering lack of awareness among migraineurs. Some estimates state that as many as 54% of patients were unaware that their headaches represented migraine [32]. The most common self-reported diagnoses in migraineurs are sinus headache (39%), tension-type headache (31%) and stress headache (29%) [14]. In addition, many patients believe they are suffering from cervical spine–related pain [13]. This is likely due to the common presence of posteriorly located pain, attacks triggered by poor sleep, or attacks associated with weather changes [13]. Patients presenting with aura are more likely to report and to receive a physician diagnosis of migraine [14]. Women are more likely to receive and report a diagnosis of migraine compared with men [32].
There are many factors that play a role in poor insight. Many patients appear to believe that the location of the pain is suggestive of the cause [13]. Many patients never seek out consultation for their headaches, and thus never receive a proper diagnosis [33]. Some patients may seek out medical care for their headaches, but fail to remember their diagnosis or receive an improper diagnosis [34].
Poor Adherence
The body of literature examining adherence with headache treatment is growing, but remains small [35]. In a recent systematic review of treatment adherence in pediatric and adult patients with headache, adherence rates in adults with headache ranged from 25% to 94% [35]. In this review, prescription claims data analyses found poor persistence in patients prescribed triptans for migraine treatment. In one large claims-based study, 53.8% of patients receiving a new triptan prescription did not persistently refill their index triptan [36]. Although some of these patients switched to an alternative triptan, the majority switched to a non-triptan migraine medication, including opioids and nonsteroidal anti-inflammatory drugs [36].
Cady and colleagues’ study of lapsed and sustained triptan users found that sustained users were significantly more satisfied with their medication, confident in the medication’s ability to control headache, and reported control of migraine with fewer doses of medication [37]. The authors concluded that the findings suggest that lapsed users may not be receiving optimal treatment. In a review by Rains et al [38], the authors found that headache treatment adherence declines “with more frequent and complex dosing regimens, side effects, and costs, and is subject to a wide range of psychosocial influences.”
Adherence issues also exist for migraine prevention. Less than 25% of chronic migraine patients continue to take oral preventive therapies at 1 year [24]. The reasons for this nonadherence are not completely clear, but are likely multifactorial. Preventives may take several weeks to months to become effective, which may contribute to noncompliance. In addition, migraineurs appears to have inadequate follow-up for migraine. Studies from France suggest that only 18% of those aware of their migraine diagnosis received medical follow-up [39].
Medication Overuse
While the data is not entirely clear, it is likely that overuse of as-needed medication plays a role in migraine chronification [40]. The reasons for medication overuse in the migraine population include some of the issues already highlighted above, including inadequate patient education, poor insight into diagnosis, not seeking care, misdiagnosis, and treatment nonadherence. Patients should be educated on the proper use of as-needed medication. Limits to medication use should be set during the physician-patient encounter. Patients should be counselled to limit their as-needed medication to no more than 10 days per month to reduce the risk of medication overuse headache. Ideally, opiates and barbiturates should be avoided, and never used as first-line therapy in patients who lack contraindications to NSAIDs and triptans. If their use in unavoidable for other reasons, they should be used sparingly, as use on as few as 5 to 8 days per month can be problematic [41]. Furthermore it is important to note that if patients are using several different acute analgesics, the combined total use of all as-needed pain medications needs to be less than 10 days per month to reduce the potential for medication overuse headache.
Socioeconomic Factors
Low socioeconomic status has been associated with an increased prevalence for all headache forms and an increased migraine attack frequency [42], but there appear to be few studies looking at the impact of low socioeconomic status and treatment. Lipton et al found that health insurance status was an important predictor of persons with migraine consulting a health care professional [43]. Among consulters, women were far more likely to be diagnosed than men, suggesting that gender bias in diagnosis may be an important barrier for men. Higher household income appeared to be a predictor for receiving a correct diagnosis of migraine. These researchers also found economic barriers related to use of appropriate prescription medications [43]. Differences in diagnosis and treatment may indicate racial and ethnic disparities in access and quality of care for minority patients [44].
Stigma
At least 1 study has reported that migraine patients experience stigma. In Young et al’s study of 123 episodic migraine patients, 123 chronic migraine patients, and 62 epilepsy patients, adjusted stigma was similar for chronic migraine and epilepsy, which were greater than for episodic migraine [45]. Stigma correlated most strongly with inability to work. Migraine patients reported equally high stigma scores across age, income, and education. The stigma of migraine may pose a barrier to seeking consultation and treatment. Further, the perception that migraine is “just a headache” may lead to stigmatizing attitudes on the part of friends, family, and coworkers of patients with migraine.
Conclusions and Recommendations
Migraine is a prevalent and frequently disabling condition that is underrecognized and undertreated in the primary care setting. Both physician and patient factors pose barriers to the optimal diagnosis and treatment of migraine. Remedies to address these barriers include education of both patients and physicians first and foremost. Targeting physician education in medical school and during residency training, including in primary care subspecialties, could include additional didactic teaching, but also clinical encounters in headache subspecialty clinics to increase exposure. Patient advocacy groups and public campaigns to improve understanding of migraine in the community may be a means for improving patient education and reducing stigma. Patients should be encouraged to seek out consultations for headache to reduce long-term headache disability. Management of comorbidities is paramount, and screening tools for migraine-associated disability, anxiety, depression, and medication use may be helpful to implement in the primary care setting as they are easy to use and time saving.
Recent surveys of PCPs suggest that the resource that is most desired is ready access to subspecialists for advice and “curb-side” consultation [17]. While this solution is not always practical, it may be worthwhile exploring closer relationships between primary care and subspecialty headache clinics, or perhaps more access to e-consultation or telephone consultation for more rural areas. Recently, Minen et al examined education strategies for PCPs. While in-person education sessions with PCPs were poorly attended, multiple possibilities for further education were identified. It was suggested that PCPs having real-time access to resources during the patient encounter would improve their comfort in managing patients. This includes online databases, simple algorithms for treatment, and directions for when to refer to a neurologist [46]. In addition, it may be worthwhile to train not only PCPs but also nursing and allied health staff so that they can provide headache education to patients. This may help ease some of the time burden on PCPs as well as provide a collaborative environment in which headache can be managed [46].
Corresponding author: William S. Kingston, MD, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259.
Financial disclosures: None.
From the Mayo Clinic, Scottsdale, AZ.
Abstract
- Objective: To review the impact of migraine and explore the barriers to optimal migraine diagnosis and treatment.
- Methods: Review of the literature.
- Results: Several factors may play a role in the inadequate care of migraine patients, including issues related to poor access to care, diagnostic insight, misdiagnosis, adherence to treatment, and management of comorbidities. Both patient and physician factors play an important role and many be modifiable.
- Conclusions: A focus on education of both patients and physicians is of paramount importance to improve the care provided to migraine patients. Patient evaluations should be multisystemic and include addressing comorbid conditions as well as a discussion about appropriate use of prevention and avoidance of medication overuse.
Key words: migraine; triptans; medication overuse headache; medication adherence; primary care.
Migraine is a common, debilitating condition that is a significant source of reduced productivity and increased disability [1]. According to the latest government statistics, 14.2% of US adults have reported having migraine or severe headaches in the previous 3 months, with an overall age-adjusted 3-month prevalence of 19.1% in females and 9.0% in males [2]. In a self-administered headache questionnaire mailed to 120,000 representative US households, the 1-year period prevalence for migraine was 11.7% (17.1% in women and 5.6% in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years [3]. Migraine is an important cause of reduced health-related quality of life and has a very high economic burden [4]. This effect is even more marked in those with chronic migraine, who are even more likely to have professional and social absenteeism and experience more severe disability [4].
Migraine and headache are a common reason for primary care physician (PCP) visits. Some estimates suggest that as many as 10% of primary care consultations are due to headache [5]. Approximately 75% of all patients complaining of headache in primary care will eventually be diagnosed with migraine [6]. Of these, as many as 1% to 5% will have chronic migraine [6].
Despite the high frequency and social and economic impact of migraine, migraine is underrecognized and undertreated. A survey of US households revealed that only 13% of migraineurs were currently using a preventive thrapy while 43.3% had never used one [3]. This is despite the fact that 32.4% met expert criteria for consideration of a preventive medication [3]. The reasons for underrecognition and undertreatment are multifactorial and include both patient and physician factors.
Physician Factors
Although migraine and headache are a leading cause of physicians visits, most physicians have had little formal training in headache. In the United States, medical students spend an average of 1 hour of preclinical and 2 hours of clinical education in headache [7]. Furthermore, primary care physicians receive little formal training in headache during residency [8]. In addition to the lack of formal training, there is also a lack of substantial clinic time available to fully evaluate and treat a new headache patient in the primary care setting [8]. Headache consultations can often be timely and detail-driven in order to determine the correct diagnosis and treatment [9].
Misdiagnosis
Evidence suggests that misdiagnosis plays a large role in the suboptimal management of migraineurs. Studies have shown that as many as 59.7% of migraineurs were not given a diagnosis of migraine by their primary care provider [10]. Common mistaken diagnoses include tension-type headache [11], “sinus headache” [12], cervical pain syndrome or cervicogenic headache [13], and “stress headache” [14].
The reasons for these misdiagnoses is not certain. It may be that the patient and practitioner assume that location of the pain is suggestive of the cause [13]. This is even though more than half of those with migraine have associated neck pain [15]. A recent study suggests that 60% of migraineurs who self-reported a diagnosis of cervical pain have been subsequently diagnosed with cervicalgia by a physician [13]. If patients endorse stress as a precipitant or the presence of cervical pain, they are more likely to obtain a diagnosis other than migraine. The presence of aura in association with the headache appears to be protective against misdiagnosis [13].
Similarly, patients are often given a diagnosis of “sinus headache.” This diagnosis is often made without radiologic evidence of sinusitis and even in those with a more typical migraine headache [16]. In one survey, 40% of patients meeting criteria for migraine were given this diagnosis. Many of these patients did have nasal symptoms or facial pain without clear evidence or rhinosinusitis, and in some cases these symptoms would respond to migraine treatments [16]. This is a particularly important misdiagnosis to highlight, as attributing symptoms to sinus disease may lead to unnecessary consultations and even sinus instrumentation.
In addition to common misdiagnoses, many PCPs are unfamiliar with the “red flags” that may indicate a secondary headache disorder and are also unfamiliar with appropriate use of neuroimaging in headache patients [17].
Misuse of As-Needed Medications
Studies have suggested that a large proportion of PCPs will prescribe nonspecific analgesics for migraine rather than migraine-specific medications [18]. These treatments may include NSAIDs, acetaminophen, barbiturates, and even opiates. This appears to be the pattern even for those with severe attacks [18], suggesting that migraine-specific medications such as triptans may be underused in the primary care setting. Postulated reasons for this pattern include lack of physician knowledge regarding the specific recommendations for managing migraine, the cost of medications, as well as lack of insurance coverage for these medications [19]. Misuse of as-needed medications can lead to medication overuse headache (MOH), which is an underrecognized problem in the primary care setting [20]. In a survey of PCPs in Boston, only 54% of PCPs were aware that barbiturates can cause MOH and only 34% were aware that opiates can cause MOH [17]. The same survey revealed that approximately 20% of PCPs had never made the diagnosis of MOH [17].
Underuse of Preventive Medications
As many as 40% of migraineurs need preventive therapy, but only approximately 13% are currently receiving it [3]. Additionally, the average time from diagnosis of migraine to instituting preventive treatment is 4.3 years, and often there is only a single preventive medication trial if one is instituted [21]. The reasons for this appear to be complex. The physician factors contributing to the underuse of preventive medications include inadequate education, discomfort and inadequate time for assessments. Only 27.8% of surveyed PCPs were aware of the American Academy of Neurology guidelines for prescribing preventive medications [17].
There may be an underestimate of the disability experienced by migraineurs, which can explain some of the underuse of preventive medications. While many PCPs endorse inquiring about headache-related disability, many do not used validated scales such as the Migraine Disability Assessment Score (MIDAS) or the Headache Impact Test (HIT) [17]. In addition, patients often underreport their headache days and report only their severe exacerbations unless clearly asked about a daily headache [22]. This may be part of the reason why only 20% of migraineurs who meet criteria for chronic migraine are diagnosed as such and why preventatives may not be offered [23].
After preventatives are started, less than 25% of patients will be adherent to oral migraine preventive agents at 1 year [24]. Common reasons for discontinuing preventives include adverse effects and perceived inefficacy [22]. Preventive medications may need a 6- to 8-week trial before efficacy is determined, but in practice medications may be stopped before this threshold is reached. Inadequate follow-up and lack of detail with regard to medication trials may result in the perception of an intractable patient prematurely. It has been suggested that a systematic approach to documenting and choosing preventive agents is helpful in the treatment of migraine [25], although this is not always practical in the primary care setting.
Another contributor to underuse of effective prophylaxis is related to access. Treatment with onabotulinumtoxin A, an efficacious prophylactic treatment approved for select chronic migraine patients [26], will usually require referral to a headache specialist, which is not always available to PCPs in a timely manner [7].
Nonpharmacologic Approaches
Effective nonpharmacologic treatment modalities for migraine, such as cognitive-behavioral therapy and biofeedback [27], are not commonly recommended by PCPs [17]. Instead, there appears to be more focus on avoidance of triggers and referral to non–evidence-based resources, such as special diets and massage therapy [17]. While these methods are not always inappropriate, it should be noted that they often have little or no evidence for efficacy.
Patients often wish for non-medication approaches to migraine management, but for those with significant and severe disability, these are probably insufficient. In these patients, non-medication approaches may best be used as a supplement to pharmacological treatment, with education on pharmacologic prevention given. Neuromodulation is a promising, novel approach that is emerging as a new treatment for migraine, but likely will require referral to a headache specialist.
Suboptimal Management of Migraine Comorbidities
There are several disorders that are commonly comorbid with migraine. Among the most common are anxiety, depression, medication (and caffeine) overuse, obesity, and sleep disorders [22]. A survey of PCPs reveals that only 50.6% of PCPs screen for anxiety, 60.2% for depression, and 73.5% for sleep disorders [17]. They are, for the most part, modifiable or treatable conditions and their proper management may help ease migraine disability.
In addition, the presence of these comorbidities may alter choice of treatment, for example, favoring the use of an serotonin and norepinephrine reuptake inhibitor such as venlafaxine for treatment in those with comorbid anxiety and depression. It is also worthwhile to have a high index of suspicion for obstructive sleep apnea in patients with headache, particularly in the obese and in those who endorse nonrestorative sleep or excessive daytime somnolence. It appears that patients who are adherent to the treatment of sleep apnea are more likely to report improvement in their headache [28].
Given the time constraints that often exist in the PCP office setting, addressing these comorbidities thoroughly is not always possible. It is reasonable, however, to have patients use screening tools while in the waiting room or prior to an appointment, to better identify those with modifiable comorbidities. Depression, anxiety, and excessive daytime sleepiness can all be screened for relatively easily with tools such as the PHQ-9 [29], GAD-7 [30] and Epworth Sleepiness Scale [31], respectively. A positive screen on any of these could lead the PCP to further investigate these entities as a possible contributor to migraine.
Patient Factors
In addition to the physician factors identified above, patient factors can contribute to the suboptimal management of migraine as well. These factors include a lack insight into diagnosis, poor compliance with treatment of migraine or its comorbidities, and overuse of abortive medications. There are also less modifiable patient factors such as socioeconomic status and the stigma that may be associated with migraine.
Poor Insight Into Diagnosis
Despite the high prevalence and burden of migraine in the general population, there is a staggering lack of awareness among migraineurs. Some estimates state that as many as 54% of patients were unaware that their headaches represented migraine [32]. The most common self-reported diagnoses in migraineurs are sinus headache (39%), tension-type headache (31%) and stress headache (29%) [14]. In addition, many patients believe they are suffering from cervical spine–related pain [13]. This is likely due to the common presence of posteriorly located pain, attacks triggered by poor sleep, or attacks associated with weather changes [13]. Patients presenting with aura are more likely to report and to receive a physician diagnosis of migraine [14]. Women are more likely to receive and report a diagnosis of migraine compared with men [32].
There are many factors that play a role in poor insight. Many patients appear to believe that the location of the pain is suggestive of the cause [13]. Many patients never seek out consultation for their headaches, and thus never receive a proper diagnosis [33]. Some patients may seek out medical care for their headaches, but fail to remember their diagnosis or receive an improper diagnosis [34].
Poor Adherence
The body of literature examining adherence with headache treatment is growing, but remains small [35]. In a recent systematic review of treatment adherence in pediatric and adult patients with headache, adherence rates in adults with headache ranged from 25% to 94% [35]. In this review, prescription claims data analyses found poor persistence in patients prescribed triptans for migraine treatment. In one large claims-based study, 53.8% of patients receiving a new triptan prescription did not persistently refill their index triptan [36]. Although some of these patients switched to an alternative triptan, the majority switched to a non-triptan migraine medication, including opioids and nonsteroidal anti-inflammatory drugs [36].
Cady and colleagues’ study of lapsed and sustained triptan users found that sustained users were significantly more satisfied with their medication, confident in the medication’s ability to control headache, and reported control of migraine with fewer doses of medication [37]. The authors concluded that the findings suggest that lapsed users may not be receiving optimal treatment. In a review by Rains et al [38], the authors found that headache treatment adherence declines “with more frequent and complex dosing regimens, side effects, and costs, and is subject to a wide range of psychosocial influences.”
Adherence issues also exist for migraine prevention. Less than 25% of chronic migraine patients continue to take oral preventive therapies at 1 year [24]. The reasons for this nonadherence are not completely clear, but are likely multifactorial. Preventives may take several weeks to months to become effective, which may contribute to noncompliance. In addition, migraineurs appears to have inadequate follow-up for migraine. Studies from France suggest that only 18% of those aware of their migraine diagnosis received medical follow-up [39].
Medication Overuse
While the data is not entirely clear, it is likely that overuse of as-needed medication plays a role in migraine chronification [40]. The reasons for medication overuse in the migraine population include some of the issues already highlighted above, including inadequate patient education, poor insight into diagnosis, not seeking care, misdiagnosis, and treatment nonadherence. Patients should be educated on the proper use of as-needed medication. Limits to medication use should be set during the physician-patient encounter. Patients should be counselled to limit their as-needed medication to no more than 10 days per month to reduce the risk of medication overuse headache. Ideally, opiates and barbiturates should be avoided, and never used as first-line therapy in patients who lack contraindications to NSAIDs and triptans. If their use in unavoidable for other reasons, they should be used sparingly, as use on as few as 5 to 8 days per month can be problematic [41]. Furthermore it is important to note that if patients are using several different acute analgesics, the combined total use of all as-needed pain medications needs to be less than 10 days per month to reduce the potential for medication overuse headache.
Socioeconomic Factors
Low socioeconomic status has been associated with an increased prevalence for all headache forms and an increased migraine attack frequency [42], but there appear to be few studies looking at the impact of low socioeconomic status and treatment. Lipton et al found that health insurance status was an important predictor of persons with migraine consulting a health care professional [43]. Among consulters, women were far more likely to be diagnosed than men, suggesting that gender bias in diagnosis may be an important barrier for men. Higher household income appeared to be a predictor for receiving a correct diagnosis of migraine. These researchers also found economic barriers related to use of appropriate prescription medications [43]. Differences in diagnosis and treatment may indicate racial and ethnic disparities in access and quality of care for minority patients [44].
Stigma
At least 1 study has reported that migraine patients experience stigma. In Young et al’s study of 123 episodic migraine patients, 123 chronic migraine patients, and 62 epilepsy patients, adjusted stigma was similar for chronic migraine and epilepsy, which were greater than for episodic migraine [45]. Stigma correlated most strongly with inability to work. Migraine patients reported equally high stigma scores across age, income, and education. The stigma of migraine may pose a barrier to seeking consultation and treatment. Further, the perception that migraine is “just a headache” may lead to stigmatizing attitudes on the part of friends, family, and coworkers of patients with migraine.
Conclusions and Recommendations
Migraine is a prevalent and frequently disabling condition that is underrecognized and undertreated in the primary care setting. Both physician and patient factors pose barriers to the optimal diagnosis and treatment of migraine. Remedies to address these barriers include education of both patients and physicians first and foremost. Targeting physician education in medical school and during residency training, including in primary care subspecialties, could include additional didactic teaching, but also clinical encounters in headache subspecialty clinics to increase exposure. Patient advocacy groups and public campaigns to improve understanding of migraine in the community may be a means for improving patient education and reducing stigma. Patients should be encouraged to seek out consultations for headache to reduce long-term headache disability. Management of comorbidities is paramount, and screening tools for migraine-associated disability, anxiety, depression, and medication use may be helpful to implement in the primary care setting as they are easy to use and time saving.
Recent surveys of PCPs suggest that the resource that is most desired is ready access to subspecialists for advice and “curb-side” consultation [17]. While this solution is not always practical, it may be worthwhile exploring closer relationships between primary care and subspecialty headache clinics, or perhaps more access to e-consultation or telephone consultation for more rural areas. Recently, Minen et al examined education strategies for PCPs. While in-person education sessions with PCPs were poorly attended, multiple possibilities for further education were identified. It was suggested that PCPs having real-time access to resources during the patient encounter would improve their comfort in managing patients. This includes online databases, simple algorithms for treatment, and directions for when to refer to a neurologist [46]. In addition, it may be worthwhile to train not only PCPs but also nursing and allied health staff so that they can provide headache education to patients. This may help ease some of the time burden on PCPs as well as provide a collaborative environment in which headache can be managed [46].
Corresponding author: William S. Kingston, MD, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259.
Financial disclosures: None.
1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity and attack frequency and duration. Neurology 1994; 44(suppl 4):S24–S39
2. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015;55:21–34.
3. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–9.
4. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use amoung chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301–15.
5. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain 2012;6:124–32.
6. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systemic review. Cephalalgia 2010;30: 599–609.
7. Finkel AG. American academic headache specialists in neurology: Practice characteristics and culture. Cephalalgia 2004; 24:522–7.
8. Sheftell FD, Cady RK, Borchert LD, et al. Optimizing the diagnosis and treatment of migraine. J Am Acad Nurse Pract 2005;17:309–17.
9. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003;60:441–8.
10. De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: Influence of functional impact measures by the Headache Impact Test (HIT). Cephalalgia 2005;25:184–90.
11. Miller S, Matharu MS. Migraine is underdiagnosed and undertreated. Practitioner 2014;258:19–24.
12. Al-Hashel JY, Ahmed SF, Alroughani R, et al. Migraine misdiagnosis as sinusitis, a delay that can last for many years. J Headache Pain 2013;14:97.
13. Viana M, Sances G, Terrazzino S, et al. When cervical pain is actually migraine: an observational study in 207 patients. Cephalalgia 2016. Epub ahead of print.
14. Diamond MD, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache 2007;47:355–63.
15. Aguila MR, Rebbeck T, Mendoza KG, et al. Definitions and participant characteristics of frequent recurrent headache types in clinical trials: A systematic review. Cephalalgia 2017. Epub ahead of print.
16. Senbil N, Yavus Gurer YK, Uner C, Barut Y. Sinusitis in children and adolescents with chronic or recurrent headache: A case-control study. J Headache Pain 2008;9:33–6.
17. Minen MT, Loder E, Tishler L, Silbersweig D. Migraine diagnosis and treatment: A knowledge and needs assessment amoung primary care providers. Cephalalgia 2016; 36:358–70.
18. MacGregor EA, Brandes J, Eikerman A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache 2003;33:19–26.
19. Khan S, Mascarenhas A, Moore JE, et al. Access to triptans for acute episodic migraine: a qualitative study. Headache 2015; 44(suppl 4):199–211.
20. Tepper SJ. Medication-overuse headache. Continuum 2012;18:807–22.
21. Dekker F, Dielemann J, Neven AK, et al. Preventive treatment for migraine in primary care, a population based study in the Netherlands. Cephalalgia 2013;33:1170–8.
22. Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis and management in primary care. Mayo Clin Proc 2015;90:408–14.
23. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559–66.
24. Hepp Z, Dodick D, Varon S, et al. Adherence to oral migraine preventive-medications among patients with chronic migraine. Cephalalgia 2015;35:478–88.
25. Smith JH, Schwedt TJ. What constitutes an “adequate” trial in migraine prevention? Curr Pain Headache Rep 2015;19:52.
26. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–36.
27. Silberstein SD. Practice parameter: evidence based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754–62.
28. Johnson KG, Ziemba AM, Garb JL. Improvement in headaches with continuous positive airway pressure for obstructive sleep apnea: a retrospective analysis. Headache 2013;53:333–43.
29. Altura KC, Patten SB, FIest KM, et al. Suicidal ideation in persons with neurological conditions: prevalence, associations and validation of the PHQ-9 for suicidal ideation. Gen Hosp Psychiatry 2016;42:22–6.
30. Seo JG, Park SP. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 2015;16:97.
31. Corlateanu A, Pylchenko S, DIrcu V, Botnaru V. Predictors of daytime sleepiness in patients with obstructive sleep apnea. Pneumologia 2015;64:21–5.
32. Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs – a nation-wide population-based survey in Sweden. Cephalalgia 2004;24:455–65.
33. Osterhaus JT, Gutterman DL, Plachetka JR. Health care resources and lost labor costs of migraine headaches in the United States. Pharmacoeconomics 1992;36:69–76.
34. Tepper SJ, Dahlof CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache 2004;44:856–64.
35. Ramsey RR, Ryan JL, Hershey AD, et al. Treatment adherence in patients with headache: a systematic review. Headache 2014;54:795–816.
36. Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia 2011;31:488–500.
37. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK. Predictors of adherence to triptans: factors of sustained vs lapsed users. Headache 2009;49:386–94.
38. Rains JC, Lipchik GL, Penzien DB. Behavioral facilitation of medical treatment for headache--part I: Review of headache treatment compliance. Headache 2006;46:1387–94.
39. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005;25:267–79.
40. Bigal ME, Serrano D, Buse D et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157–68.
41. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004;3:475–83.
42. Winter AC, Berger K, Buring JE, Kurth T. Associations of socioeconomic status with migraine and non-migraine headache. Cephalalgia 2012;32:159–70.
43. Lipton, RB, Serrano D, Holland S et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013;53: 81–92.
44. Loder S, Sheikh HU, Loder E. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. Headache 2015;55:214–28.
45. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013;8:e54074.
46. Minen A, Shome A, Hapern A, et al. A migraine training program for primary care providers: an overview of a survey and pilot study findings, lessons learned, and consideration for further research. Headache 2016;56:725–40.
1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity and attack frequency and duration. Neurology 1994; 44(suppl 4):S24–S39
2. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015;55:21–34.
3. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–9.
4. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use amoung chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301–15.
5. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain 2012;6:124–32.
6. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systemic review. Cephalalgia 2010;30: 599–609.
7. Finkel AG. American academic headache specialists in neurology: Practice characteristics and culture. Cephalalgia 2004; 24:522–7.
8. Sheftell FD, Cady RK, Borchert LD, et al. Optimizing the diagnosis and treatment of migraine. J Am Acad Nurse Pract 2005;17:309–17.
9. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003;60:441–8.
10. De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: Influence of functional impact measures by the Headache Impact Test (HIT). Cephalalgia 2005;25:184–90.
11. Miller S, Matharu MS. Migraine is underdiagnosed and undertreated. Practitioner 2014;258:19–24.
12. Al-Hashel JY, Ahmed SF, Alroughani R, et al. Migraine misdiagnosis as sinusitis, a delay that can last for many years. J Headache Pain 2013;14:97.
13. Viana M, Sances G, Terrazzino S, et al. When cervical pain is actually migraine: an observational study in 207 patients. Cephalalgia 2016. Epub ahead of print.
14. Diamond MD, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache 2007;47:355–63.
15. Aguila MR, Rebbeck T, Mendoza KG, et al. Definitions and participant characteristics of frequent recurrent headache types in clinical trials: A systematic review. Cephalalgia 2017. Epub ahead of print.
16. Senbil N, Yavus Gurer YK, Uner C, Barut Y. Sinusitis in children and adolescents with chronic or recurrent headache: A case-control study. J Headache Pain 2008;9:33–6.
17. Minen MT, Loder E, Tishler L, Silbersweig D. Migraine diagnosis and treatment: A knowledge and needs assessment amoung primary care providers. Cephalalgia 2016; 36:358–70.
18. MacGregor EA, Brandes J, Eikerman A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache 2003;33:19–26.
19. Khan S, Mascarenhas A, Moore JE, et al. Access to triptans for acute episodic migraine: a qualitative study. Headache 2015; 44(suppl 4):199–211.
20. Tepper SJ. Medication-overuse headache. Continuum 2012;18:807–22.
21. Dekker F, Dielemann J, Neven AK, et al. Preventive treatment for migraine in primary care, a population based study in the Netherlands. Cephalalgia 2013;33:1170–8.
22. Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis and management in primary care. Mayo Clin Proc 2015;90:408–14.
23. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559–66.
24. Hepp Z, Dodick D, Varon S, et al. Adherence to oral migraine preventive-medications among patients with chronic migraine. Cephalalgia 2015;35:478–88.
25. Smith JH, Schwedt TJ. What constitutes an “adequate” trial in migraine prevention? Curr Pain Headache Rep 2015;19:52.
26. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–36.
27. Silberstein SD. Practice parameter: evidence based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754–62.
28. Johnson KG, Ziemba AM, Garb JL. Improvement in headaches with continuous positive airway pressure for obstructive sleep apnea: a retrospective analysis. Headache 2013;53:333–43.
29. Altura KC, Patten SB, FIest KM, et al. Suicidal ideation in persons with neurological conditions: prevalence, associations and validation of the PHQ-9 for suicidal ideation. Gen Hosp Psychiatry 2016;42:22–6.
30. Seo JG, Park SP. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 2015;16:97.
31. Corlateanu A, Pylchenko S, DIrcu V, Botnaru V. Predictors of daytime sleepiness in patients with obstructive sleep apnea. Pneumologia 2015;64:21–5.
32. Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs – a nation-wide population-based survey in Sweden. Cephalalgia 2004;24:455–65.
33. Osterhaus JT, Gutterman DL, Plachetka JR. Health care resources and lost labor costs of migraine headaches in the United States. Pharmacoeconomics 1992;36:69–76.
34. Tepper SJ, Dahlof CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache 2004;44:856–64.
35. Ramsey RR, Ryan JL, Hershey AD, et al. Treatment adherence in patients with headache: a systematic review. Headache 2014;54:795–816.
36. Katic BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia 2011;31:488–500.
37. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK. Predictors of adherence to triptans: factors of sustained vs lapsed users. Headache 2009;49:386–94.
38. Rains JC, Lipchik GL, Penzien DB. Behavioral facilitation of medical treatment for headache--part I: Review of headache treatment compliance. Headache 2006;46:1387–94.
39. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005;25:267–79.
40. Bigal ME, Serrano D, Buse D et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157–68.
41. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004;3:475–83.
42. Winter AC, Berger K, Buring JE, Kurth T. Associations of socioeconomic status with migraine and non-migraine headache. Cephalalgia 2012;32:159–70.
43. Lipton, RB, Serrano D, Holland S et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013;53: 81–92.
44. Loder S, Sheikh HU, Loder E. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. Headache 2015;55:214–28.
45. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013;8:e54074.
46. Minen A, Shome A, Hapern A, et al. A migraine training program for primary care providers: an overview of a survey and pilot study findings, lessons learned, and consideration for further research. Headache 2016;56:725–40.